Group B Streptococcus serotype Ib capsular polysaccharide

Group B Streptococcus serotype Ib capsular polysaccharide is a surface-associated, high-molecular-weight carbohydrate structure produced by serotype Ib strains of Group B Streptococcus (GBS), a pathogenic bacterium implicated in neonatal sepsis, meningitis, and infections in immunocompromised individuals[2][4][5]. Like other GBS capsular polysaccharides, type Ib CPS is composed primarily of repeating units of five monosaccharides—glucose, galactose, N-acetylglucosamine, and sialic acid—with a characteristic pentasaccharide structure and a distinctive β-(1→3) linkage within its trisaccharide side chain that defines its serotype-specific antigenicity[4][5]. The polysaccharide capsule serves as a major virulence determinant, allowing the bacteria to evade host immunity by inhibiting complement activation and phagocytosis, and contributes to the pathogen’s resistance in human plasma[4][5]. The serotype Ib CPS is an established antigenic target for vaccine development, with polysaccharide-protein conjugate vaccines under investigation to induce protective antibody responses, since unmodified polysaccharides are poorly immunogenic in vulnerable populations such as infants[1][4][5]. No small-molecule drugs are known to interact directly with Ib CPS; therapeutic interventions focus on immunological principles, notably vaccination and antibody-mediated neutralization[1][5].

Other names

GBS serotype Ib capsular polysaccharideGBS type Ib capsuleGroup B Streptococcus type Ib CPSGBS Ib CPS

Target of neutralizing and opsonophagocytic antibodies (as in vaccine-induced immunity) Inhibitor of complement activation (intrinsic function)